Literature DB >> 24210698

Perioperative image-adapted brachytherapy for the treatment of paranasal sinus and nasal cavity malignancies.

Ingo U Teudt1, Jens E Meyer2, Matthias Ritter3, Barbara Wollenberg3, Torsten Kolb2, Steffen Maune4, György Kovàcs5.   

Abstract

PURPOSE: Sinonasal malignancies are a rare group of cancers often associated with late presentation and poor prognosis. In the past, there was little progress regarding survival rate, and often, multimodal treatment regimens are required. The aim of this study was to evaluate the clinical outcome of perioperative image-adapted brachytherapy (IABT) as part of a multidisciplinary treatment regimen for the therapy of sinonasal cancer. METHODS AND MATERIALS: Since 2006, patients with sinonasal cancer at the University Hospital of Schleswig-Holstein Campus Luebeck, Germany, were offered a multimodal treatment concept including head and neck surgery, perioperative IABT with or without external beam radiation therapy, and chemotherapy. In a retrospective study, such patients were analyzed for survival rate, tumor control, and toxicity of the interdisciplinary treatment.
RESULTS: Thirty-five consecutive patients were analyzed. The majority of patients (63%) were treated for a primary tumor and 62% presented with tumor Stages III-IV. The mean follow-up time with IABT was 28 months. Overall survival estimate was 72% after 3 years. Disease-specific survival, disease-free survival, and local control rates were 83%, 63%, and 67%, respectively. On univariate analysis, a significant better disease-free survival rate was found in patients treated for primary, but not recurrent, sinonasal cancer (p = 0.006). The overall treatment toxicities were mainly classified Grade I.
CONCLUSIONS: Interdisciplinary perioperative IABT is associated with excellent locoregional control and survival rates. IABT is well tolerated and shows low toxicity. Furthermore, visual acuity can be preserved in advanced cases. The implementation of perioperative IABT into multimodal treatment regimens improves the oncologic outcome.
Copyright © 2014 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Brachytherapy tube; Multimodal treatment; Nasal cavity cancer; Paranasal sinus cancer; Survival; Toxicity

Mesh:

Year:  2013        PMID: 24210698     DOI: 10.1016/j.brachy.2013.10.009

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  6 in total

1.  Intensity modulated perioperative HDR brachytherapy for recurrent and/or advanced head and neck metastases.

Authors:  Ingo U Teudt; György Kovàcs; Matthias Ritter; Corinna Melchert; Tamer Soror; Barbara Wollenberg; Jens E Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-23       Impact factor: 2.503

Review 2.  [Tumors of the paranasal sinus invading the orbit].

Authors:  M Herzog
Journal:  HNO       Date:  2018-10       Impact factor: 1.284

Review 3.  The role of brachytherapy in the treatment of squamous cell carcinoma of the head and neck.

Authors:  Małgorzata Wierzbicka; Anna Bartochowska; Vratislav Strnad; Primož Strojan; William M Mendenhall; Louis B Harrison; Alessandra Rinaldo; Puja Sahai; Susanne Wiegand; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-22       Impact factor: 2.503

Review 4.  Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.

Authors:  György Kovács
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

5.  Successful salvage treatment of refractory recurrence of maxillary sinus carcinoma using image-guided high-dose-rate interstitial brachytherapy.

Authors:  Yin Zhang; Ning Wu; Zhipeng Zhao; Qianqian Chen; Guanghui Cheng
Journal:  J Contemp Brachytherapy       Date:  2018-04-30

6.  Perioperative high dose rate brachytherapy in head and neck cancers: case report and review of clinical application.

Authors:  Amit Bahl; Roshan K Verma; Naresh K Panda; Arun S Oinam; Jerry R John; Satinder Kaur; Pramod Kumar; Sushmita Ghoshal; Gaurav Trivedi; Jaimanti Bakshi
Journal:  BJR Case Rep       Date:  2021-04-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.